WHAT IS CLAIMED IS:

- 1. A method of inhibiting human immunodeficiency virus (HIV) ribonucleotide reductase (Rr) in a subject infected with HIV comprising administering to said subject an amount of a gallium composition effective to inhibit Rr.
- 5 2. The method of claim 1, wherein HIV is HIV-1.
 - 3. The method of claim 1, wherein HIV is HIV-2.
 - 4. The method of claim 1, wherein HIV has infected a T-cell.
 - 5. The method of claim 1, wherein said gallium composition is gallium nitrate.
 - 6. The method of claim 1, wherein said gallium composition is a gallium-hydroxypyrone complex.
 - 7. A method of inhibiting human immunodeficiency virus (HIV) replication in a subject infected with HIV comprising administering to said subject an amount of a gallium composition effective to inhibit HIV replication.
 - 8. The method of claim 7, wherein HIV is HIV-1.
 - 9. The method of claim 7, wherein HIV is HIV-2.
 - 10. The method of claim 1, wherein HIV has infected a T-cell.
 - 11. A method of treating a human subject infected with human immunodeficiency virus (HIV) comprising administering to said subject an amount of a gallium composition effective to inhibit HIV replication.
- 20 12. The method of claim 11, wherein HIV is HIV-1.
 - 13. The method of claim 11, wherein HIV is HIV-2.
 - 14. The method of claim 11, wherein said gallium composition is gallium nitrate.

10


15

- 15. The method of claim 11, wherein said gallium composition is a gallium-hydroxypyrone complex.
- 16. The method of claim 11, wherein said effective amount achieves in vivo concentrations of about 1 to about 30 μ M.
- 5 17. The method of claim 16, wherein said effective amount is about 3 to about 20 μM .
 - 18. The method of claim 11, wherein said effective amount is about 750 mg/m² given every two to three weeks.
 - 19. The method of claim 11, wherein said effective amount is about 100 to about 300 mg/m² per day.
 - 20. The method of claim 11, wherein said effective amount is given in a unit dose of about 200 mg to about 1000 mg.
 - 21. The method of claim 11, wherein said gallium composition is administered orally.
 - 22. The method of claim 21, wherein said gallium composition is in the form of a tablet.
 - 23. The method of claim 21, wherein said gallium composition is in the form of a capsule.
 - 24. The method of claim 11, wherein said gallium composition is administered intravenously.
- 25. The method of claim 11, wherein said gallium composition is sufficient to provide a blood plasma gallium concentration of 0.1 to 5.0 μg/ml.
 - 26. The method of claim 11, further comprising treating said subject with a second anti-viral agent.

10.

15

20



- 28. The method of claim 26, wherein said NRTI is didexoyinosine.
- 29. The method of claim 26, wherein said NRTI is dideoxycytidine.
- 5 30. The method of claim 26, wherein said NRTI is 5-azidothymidine.
 - 31. A method of reducing virus shed from a human subject infected with human immunodeficiency virus (HIV) comprising administering to said subject an amount of a gallium composition effective to inhibit HIV replication.
 - 32. A method of reducing virus burden in a human subject infected with human immunodeficiency virus (HIV) comprising administering to said subject an amount of a gallium composition effective to inhibit HIV replication.
 - 33. A method of inhibiting loss of T cells in a human subject infected with human immunodeficiency virus (HIV) comprising administering to said subject an amount of a gallium composition effective to inhibit HIV replication.
 - 34. The method of claim 33, wherein the number of T cells in said subject increases following treatment with said gallium composition.
 - 35. A method of inhibiting development of acquired immunodeficiency syndrome in a human subject infected with human immunodeficiency virus (HIV) comprising administering to said subject an amount of a gallium composition effective to inhibit HIV replication.
 - 36. A therapeutic composition comprising:
 - (a) a gallium composition; and
 - (b) a nucleoside inhibitor.
- 25 37. The composition of claim 36, wherein said gallium composition is gallium nitrate.





- 38. The composition of claim 36, wherein said gallium composition is a gallium-hydroxypyrone complex.
- 39. The composition of claim 36, wherein the nucleoside inhibitor is one or more of the compounds selected from the group of dideoxyinosine, dideoxycytidine and 5-azidothymidine.
 - 40. A kit comprising, in suitable container means:
 - (a) a gallium composition; and
 - (b) a nucleoside reverse transcriptase inhibitor.

10

5